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Abstract
We apply a new Bayesian data analysis technique (Latent Process Decomposition) to four
recent microarray datasets for breast cancer. Compared to hierarchical cluster analysis, for
example, this technique has advantages such as objective assessment of the optimal number of
sample or gene clusters in the data, penalisation of overcomplex models fitting to noise in the
data and a common latent space of explanatory variables for samples and genes. Our analysis
provides a clearer insight into these datasets, enabling assignment of patients to one of four
principal processes, each with a distinct clinical outcome. One process is indolent and asso-
ciated with under-expression across a number of genes associated with tumour growth. One
process is associated with over-expression of GRB7 and ERBB2. The most aggressive process
is associated with abnormal expression of transcription factor genes, including members of the
FOX family of transcription factor genes.
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1 Introduction
Evidence from epidemiological studies, analysis of tumour progression and variability in response to
treatment all indicate considerable diversity among human breast cancers. This view is supported
by various independent microarray studies [6, 11, 12, 13, 21, 24, 26, 27]. For example, with one
recent study [25], hierarchical cluster analysis suggested the existence of five major categories
of breast cancer. Two groups of predominantly estrogen receptor positive (ER+) cancers had
expression patterns similar to breast luminal cells (called luminal A and B). For the ER− cancers,
three additional categories were identified that overexpressed genes associated with the ERBB2
amplicon at 17q22, had a basal cell expression pattern or resembled normal breast tissue. The
significantly different clinical outcomes of 4 of these groups (luminal A, luminal B, basal and
ERBB2) highlighted the potential biological importance of this classification. Although these
groups could be broadly defined, the fine structure of dendrograms varied between individual
cluster analysis methods and the authors concluded that the observed high level branching was
not always a reflection of biologically meaningful relationships.
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In this paper we will use a new Bayesian approach for finding informative structure in such datasets.
This approach is called Latent Process Decomposition (LPD) [23] and it is modelled on the Latent
Dirichlet Allocation method of Blei et al [2]. In the derived model each sample (or gene expression
measurement) is represented as a combinatorial mixture over a finite set of latent processes (a
process is an assumed functionally related set of samples or genes). Observations are not necessarily
assigned to a single cluster. This reflects a prior belief that a number of processes could contribute
to a given gene expression level or that a tumour could have a heterogeneous structure because it
overlaps several defined states. By contrast, most cluster analysis methods use an implicit mutual
exclusion of classes assumption, though several algorithms which avoid this assumption have been
proposed recently [10, 19, 3]. The proposed approach has other advantages. For example, the
optimal number of sample or gene clusters can be objectively assessed. Also samples and gene
expression levels are modelled using a common space of explanatory variables. This is in contrast to
the use of dendrograms where samples and gene expression values are typically clustered separately,
amounting to two distinct reduced space representations which are not easily related. LPD can
also readily handle missing values. Finally LPD has the advantage that we can incorporate a prior
belief that experimental noise exists and thus use a Bayes prior penalising overcomplex models
which would fit the noise. LPD also compares favourably to various cluster analysis methods [23].
To illustrate its potential we apply this approach to breast cancer datasets from Sorlie et al [25],
West et al [27], van ’t Veer et al [26] and de Vijver et al [6]. The method appears to give clearer
insights into these datasets suggesting at least 4 principal processes, each associated with a different
clinical outcome. The results presented in the next section derive from a variational approach to
Latent Process Decomposition described in Appendix 2 (the reader is referred to Rogers et al [23] for
a full description). To support these results we have additionally used a Markov Chain Monte Carlo
(MCMC) approach to LPD, described in Appendix 2. The latter proved more computatonally
demanding than the variational approach, but gives a very similar picture.
2 The Application of Latent Process Decomposition to four
Microarray Datasets for Breast Cancer
2.1 Sorlie et al dataset.
From the study of Sorlie et al [24] we used data from 115 primary breast carcinoma samples (labelled
Norway/Stanford and very predominantly of invasive ductal type) and we used the same set of 534
genes selected in their study. In Figure 1 we give the log-likelihood curves for both a maximum
likelihood and MAP (maximum a posterior) model using variational LPD [23]. For the maximum
likelihood model the log-likelihood has an approximate peak at about 4 processes indicating this
is a suitable number of processes to use. For the MAP model (Figure 1, upper curve) a Bayesian
prior has been used to penalise construction of an over-complex model. The log-likelihood rises
to a plateau after which no further gain is to be made by introducing further processes since
the model will not exploit this extra freedom. In contrast, for the maximum likelihood solution,
the log-likelihood falls as further processes are introduced since the algorithm will use these and
construct an over-complex model.
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Figure 1: The log-likelihood (y-axis) versus number of processes (x-axis) using the MAP solu-
tion (upper curve) and maximum likelihood solution (lower curve) for the Sorlie et al dataset
Stanford/Norway dataset [24].
Using a 4 process model we can derive the decomposition diagram in Figure 2 where the peaks
represent the confidence that sample a is assigned to process k (these peaks are given by normalised
γak parameters, see Appendix 2, equation (4) for further details). Unlike most cluster analysis
methods, samples can belong to several processes simultaneously.
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Figure 2: Decomposition diagram derived from LPD for the dataset of Sorlie et al. The top process
is identified with the trend curve 3 in Figure 3(a), the second process is identified with 2, the third
with 4 and the lowest is identified with the indolent process 1 in Figure 3(a).
We have used a threshold of 0.5 for assignment of sample a to process k and determined the
corresponding Kaplan-Meier plot in Figure 3(a). The separation is more distinct than that made
by the original authors [25] with one indolent subtype and three aggressive subtypes indicated.
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(a) KM1
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(b) KM2
Figure 3: Kaplan-Meier plots for the Sorlie et al dataset. The graphs show fraction not expired
from the disease (y-axis) versus number of months (x-axis). For KM1 (left) there are 9 patients in
process 1, 32 in 2, 48 in 3 and 18 in 4 (the remaining 8 samples are insufficiently identified with
a process). A vertical drop indicates expiry from the disease and a star indicates the patient is
not recorded as expired from the disease (this includes the point at which some patients exited
the survey). KM2 corresponds to a different initialisation of the algorithm (see text) with 7, 23,
58 and 18 patients assigned to processes 1 to 4 respectively. With different initialisations there
is some variability in the assignment of patients to processes 1 to 3, though process 4 remains
quite distinct with 18 patients usually assigned, both using the variational LPD used here and the
alternative MCMC approach described in Appendix 2 (see Figure 18(a)).
The likelihood function is not concave (local maxima can exist). Local maxima correspond to
models with good fits to the data with the intervening regions in model space corresponding to
poorer fits. Nevertheless, it is likely that models with good fits are sharply concentrated in model
space. However, this does mean different initialisations of the algorithm can give different solutions.
In fact, since many peaks in Figure 2 are near 0.5, the Kaplan-Meier plot is the most sensitive
result dependent on this effect. Figure 3(b) is a typical result from a different initialisation in which
some patients have moved between the outcome trends. To investigate this issue we restarted the
algorithm with 50 randomly constructed initialisations and found that 32 of these gave a Kaplan-
Meier plot in which no patient had expired from the disease in process 1. Furthermore, these
32 solutions had a distinctly higher average log-likelihood than those solutions with at least one
patient expiring from the disease in process 1, indicating they are more appropriate models (Figure
4).
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Figure 4: With 50 random initialisations, 32 instances gave Kaplan Meier plots with a purely
indolent process 1 (lower histogram) and 18 cases had at least one patient expiring from the disease
(upper histogram). The x-axis gives the value of the log-likelihood and the y-axis the frequency of
occurence. Solutions with a purely indolent process 1 gave a higher average log-likelihood indicating
they give a better fit to the data.
Apart from identifying samples with processes, LPD can be used to identify those genes which
are most prominent in distinguishing processes. From the algorithm (equations (5,6,11,12) in
Appendix 2), we can determine a mean µk and standard deviation σk for each process k and hence
inferred density curves (estimating amount of data in a region). An example of two density curves
is given in Figures 5(a) and 5(b). These density curves are derived from the dataset taken as a
whole and are not one-dimensional fits to the expresssion values for that gene. We can thus use
a score Z1 = |µ1 − µ2|/
√
σ21 + σ
2
2 to rank genes distinguishing processes 1 and 2, for example,
and this score follows a normal probability distribution with N (0, 1). Apart from comparing two
processes we could also compare one process with the rest e.g. by using the lowest pairwise Z1-
score. Unfortunately this score can be adversely influenced by large variances. Thus the gene
depicted in Figure 7(a) does not score well because it has a large variance in the denominator
of Z1. Consequently we will also use a second, rank-based, score (based on the Mann-Whitney
test [22]) to highlight such cases. This score will be denoted Z2 and quantifies the probability of
observing a sequence of ranked and labelled datapoints (ranked by expression level and labelled 1
(process of interest) or 2 (other processes)).
No single gene is a particularly distinct marker for process 1. However, of the top 20 ranked genes
distinguishing process 1 from the rest, all but one exhibit relative under-expression in process 1.
For the three aggressive processes (2-4), process 4 has the most distinctive genes and process 2
the least distinctive (the highest ranked gene is LIV-1). Using the Z1-score the most distinctive
gene in process 3 is GRB7, depicted in Figure 5(a). It has a score Z1 = 3.84 (p = 0.00006) with
only Z1 = 1.59 (p = 0.06) for the next highest ranked gene (PAPSS2). GRB7 is an adaptor-type
signaling protein which is recruited via its SH2 domain to a variety of receptor tyrosine kinases
(RTKs), including ERBB2 and ERBB3. It is overexpressed in breast, esophagal and gastric cancers,
and may contribute to invasiveness potential [20]. It is frequently co-amplified with ERBB2 (HER2)
in breast cancer and from Figure 5(b) we see that ERBB2 is, indeed, only overexpressed in process
3.
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Figure 5: Inferred densities for GRB7 and ERBB2 for the Sorlie et al dataset, with + the expression
values for samples identified with process 3. Though only over-expressing in process 3 a subset of
samples do not over-express GRB7 suggesting a possible subprocess within this process. In this
and subsequent figures individual expression values are marked ◦ if the samples are associated with
process 1, × with 2, + with 3 and · if associated with process 4.
Process 4 has the most distinctive set of genes. In agreement with previous observations [25], this
process has basal cell characteristics e.g. cytokeratin 5 appears up-regulated. Using the Z1 score the
top ranked gene distinguishing process 4 is FLT1 (VEGFR1) (Figure 6). VEGFR1 (especially its
soluble isoform) is a negative regulator of vascular endothelial growth factor availibility. Indeed,
VEGFR1 overexpression is associated with improved survival in breast cancer [28]. Estrogen
mediated decrease in VEGFR1 expression can cause increased angiogenesis leading to enhanced
breast tumour progression [9].
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Figure 6: Inferred densities for FLT1 (VEGFR1) in process 4 with · denoting the corresponding
expression values.
The second ranked gene by Z1-score is MAFG which is associated with upregulation of protective
anti-oxidant enzymes under cellular conditions of oxidative stress [14]. Third ranked is FOXC1, a
gene which expresses a forkhead transcription factor. The fourth ranked gene is XBP1 expressing
an X box binding protein and the fifth ranked gene expresses AD021 protein. In the table below
we list the top 12 probes ranked by the Z2 score for process 4.
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Rank Gene Z2-score Expression
1. TFF3 6.35 Under
2. FOXC1 6.32 Over
3. FOXA1 6.30 Under
4. XBP1 6.25 Under
5. GATA3 6.11 Under
6. B3GNT5 6.08 Over
7. FLJ14525 6.05 Over
8. FLT1 6.04 Under
9. GALNT10 5.95 Under
10. FOXC1 5.88 Over
11. FBP1 5.76 Under
12. GATA3 5.68 Under
Table 1: The top ranked genes distinguishing process 4 by Z2-score for the dataset of Sorlie et
al. Z2 follows a normal distribution with N (0, 1) thus the associated probabilities of occurrence
are upper bounded by 10−8 reflecting the fact that the ordering of expression values for process
4 against the set of expression values for the other processes is highly improbable according to a
null hypothesis. In the original data the FOXC1 clone is annotated as FLJ11796 and FOXA1 as
HNF3A.
FOXA1 and FOXC1 are members of the forkhead family of transcription factor genes (Figure 7).
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Figure 7: FOXA1 (HNF3A) underexpresses while FOXC1 overexpresses in process 4 (· denotes the
expression values in process 4).
FOXA1, GATA3 and XBP1 encode transcription factors and their roles and association with the
estrogen receptor-α gene (ESR1) and trefoil factors (TFF3 and TFF1) are reviewed by Lacroix
and Leclerq [15].
In Appendix 1 we give the original dendrogram decomposition reported in Sorlie et al [25] along
with the assignment to processes given in Figure 2. Sorlie et al [25] labelled a subset of the tumour
samples as Luminal A and B, ERBB2+ and Basal. Their 18 Basal tumours match the 18 Process
4 samples. Indeed, we shall later see that this process is very distinctive. Elsewhere LPD labels a
wider range of samples than labelled by Sorlie et al (though this would depend on the threshold
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chosen for the significance of the peaks in Figure 2). Their 11 Luminal B and 11 ERBB2+ are
exclusively subsets of process 3, while their 28 Luminal A are exclusively associated with processes
1 and 2. Indolent process 1 is exclusively sampled from some Luminal A samples and other samples
which were left unlabelled in their study. If we use the MCMC-based approach to LPD we obtain
a very similar picture (see Figure 18).
2.2 West et al dataset.
For the Affymetrix breast cancer dataset of West et al [27] we used data from 49 samples (exclu-
sively derived from tumours of invasive ductal type) with 500 probes ordered using the p-values
derived by the authors (though LPD can readily handle the full dataset, some feature selection
is advisable since redundant information injects noise into the analysis). No survival data was
available for this dataset, though time-to-metastasis was available. Nevertheless we can derive the
corresponding MAP solution (Figure 8).
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Figure 8: The log-likelihood (y-axis) versus number of processes (x-axis) using a MAP approach
(right) for the West et al dataset.
The onset of the plateau is more ambiguous in this case and could indicate up to 5 processes. How-
ever, to conform with the analysis elsewhere we will use 4. We then get the following decomposition
diagram:
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Figure 9: Decomposition diagram derived from LPD for the dataset of West et al.
As observed previously, process 4 has the most distinctive genetic signature which, from time-
to-metastasis data, appears identified with the second row in Figure 9. The top-ranked genes
distinguishing this process are given in the Table below:
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Rank Gene Z2-score Expression
1. hCRHP 5.51 Under
2. XBP1 5.50 Under
3. FOXA1 5.26 Under
4. FPB1 4.98 Under
5. FLJ13710 4.94 Under
6. GATA3 4.94 Under
7. GATA3 4.92 Under
8. CNAP1 4.90 Over
9. NFIB2 4.83 Over
10. Human complement factor B 4.83 Under
11. TFF3 4.79 Under
12. FLJ13710 4.78 Under
Table 2: Top ranked genes using the Z2-score distinguishing a tentative process 4. Using the Z1
score GATA3 is ranked 2nd, FOXA1 is 3rd, XPB1 is 4th and TFF3 is 6th. The probabilities of
occurrence are upper bounded by 2× 10−6 (for Z2 = 4.78).
Interestingly, GATA3, FOXA1, XPB1, TFF3 and FPB1 are in common between this Table and
Table 1. Though GRB7 and ERBB2 were highlighted previously [25] the associated p-values and
sample sizes indicate they do not have a statistically significant elevated expression here, though
this fact most likely stems from the smaller dataset size.
2.3 van ’t Veer et al dataset.
For the dataset of van ’t Veer et al [26] we used samples from 78 patients with primary breast
carcinomas, a further 18 samples from patients with BRCA1 germline mutations and 2 samples
with BRCA2 mutations. We used 500 genes selected using the p-values derived by the authors
[26], using those genes with a p-value of less than 0.01 in more than 30 tumours. Survival data is
not available though we can still compute the log-likelihood curves (Figure 10) and this suggests
a peak at 4 processes.
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Figure 10: The log-likelihood (y-axis) versus number of processes (x-axis) using the MAP solution
(upper, plateauing curve) and maximum likelihood (lower curve) solution for the Van ’t Veer et al
dataset [26].
The spectrum of peaks corresponding to Figure 2 indicated that 16 of the 18 BRCA1 mutation
9
Rank Gene Z2-score Expression
1. TFF3 7.02 Under
2. AGR2 6.89 Under
3. FOXC1 6.79 Over
4. GABA 6.75 Over
5. VGLL1 6.68 Over
Table 3: TFF3 and FOXC1 are first and third ranked for the most distinctive process in the
dataset of van ’t veer et al. Similarly they are first and second ranked for the most distinctive and
aggressive process (4) in the data of Sorlie et al (Table 1).
carriers belonged in one process (which, from the time to metastasis data, appeared to be process
4 in Figure 3(b)). The other 2 BRCA1 samples were spread between processes and, interestingly,
were the only 2 patients not to proceed to metastasis. The two BRCA2 samples belonged together
in the same process, distinct from the process associated with the BRCA1 samples. This picture
agreed with the interpretation by dendrogram of Sorlie et al [25].
Using the Z1-score, one process has ERRB2 (Figure 11(a)) and GRB7 (Figure 11(b)) in second
and third ranked position with the distribution of expression values having a similar bimodal
distribution to that in Figures 5(a) and 5(b).
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Figure 11: Inferred densities for GRB7 and ERBB2 for the dataset of van ’t Veer et al.
The highest ranked Z2-scores for genes in the four processes are 7.02, 5.85, 5.61 and 2.87. Interest-
ingly, the most distinctive process (with Z2 = 7.02) is associated with genes described previously
for process 4, such as TFF3 and FOXC1 (Table 3). TFF3, and the GATA3, FOXA1 and XPB1
genes mentioned previously, all feature in a small gene expression graph derived from a sparse
graphical model [7, 8] indicating genes closely linked with the estrogen receptor gene.
2.4 de Vijver et al dataset.
The study of van ’t veer et al preceded a larger study by de Vijver et al [6] which used 295 samples
from patients with primary breast carcinomas. The authors of this study discovered tentative
signatures for poor and good prognosis using a reduced 70 gene set selected from 24,479. In
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Figure 14 we present a Kaplan-Meier plot with the lower dashed curve corresponding to patients
in the poor signature cohort and the upper dashed curve corresponding to the good signature
cohort. In Figure 12(a) we have re-analysed the same dataset (295 samples, 70 features) using
variational LPD and a maximum likelihood approach. The curve shows a peak in the range 4 to 6
processes, implying that the 2-process model proposed by the original authors [6] is a sub-optimal
interpretation of the data. In Figure 12(b) we see that the likelihood curve for the MAP solution
plateaus after using 4 processes.
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(a) Maximum likelihood solution
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Figure 12: The log-likelihood (y-axis) versus number of processes (x-axis) using a maximum like-
lihood and MAP approach for the de Vijver et al dataset.
If we plot the corresponding Kaplan-Meier curves for Figure 13 we get the curves in Figure 14
in which the top process in Figure 13 is identified with curve 3 in Figure 14, the second process
is identified with curve 4, the third process with 2 and the fourth (lowest) with 1. Compared to
the original analysis of de Vijver et al (dashed curves in Figure 14), all patients in processes 3
and 4 derive from their lower (poor prognosis) group while 10 patients in process 1 are derived
from their upper (good prognosis) group and 2 are derived from their poor prognosis group. All
patients in process 2 derive from their good prognosis group. Thus our analysis is compatible with
their description while enhancing the distinction between clinical outcomes (the solution presented
here corresponds to the highest likelihood solution found in numerical experiments). With the
MCMC-based algorithm we obtain a very similar Kaplan-Meier plot (Figure 19).
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Figure 13: A 4 process decomposition of the data by LPD. The data is not in the same order as
the dendrogram.
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Figure 14: Kaplan-Meier plot for the processes identified in Figure 13: fraction not expired from
the disease (y-axis), versus number of months (x-axis). The curves labelled 3 and 4 meet at the
midpoint but do not cross over. The number of patients identified with each curve is 12 (process 1),
97 (2), 110 (3) and 56 (4) (these numbers do not sum to 295 because some samples are ambiguously
identified). The original split of de Vijver et al [6] are given as dashed curves for comparison.
The inferred densities for two top-ranked genes separating processes 1 and 4 are given in Figures
15(a) and 15(b). In fact, of the 26 top-ranked genes separating processes 1 and 4, 21 genes
move from under-expression to over-expression as we progress from indolent to the most aggressive
subtype, following the trend in Figure 15(a), while 4 genes follow the reverse trend illustrated in
Figure 15(b).
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Figure 15: Inferred densities for ORC6L and STK32B. The individual expression values are given
below the inferred density curves, with ◦ associated with process 1, × with 2, + with 3 and · with
process 4.
The observation that most of the listed genes under-express in process 1 agrees with an observation
for the dataset of Sorlie et al in which we found that 19 from the top ranked 20 genes distinguishing
process 1 from the others under-expressed on the average in process 1. The gene names, their mean
expression values per process and this trend are discussed in further detail in Appendix 3 to this
paper.
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3 Conclusion
The results are broadly consistent and indicate at least four principal processes for primary breast
carcinoma. Our analysis suggests the existence of an indolent subtype distinguished by under-
expression across a number of genes associated with tumour growth. Since some patients in this
process do develop metastatic tumours this process is not wholly benign, nor does it consist of
misidentified normal samples. There is a subtype closely related to the Luminal A subtype proposed
by Sorlie et al [25]. In line with previous observations there is also a subtype marked by up-
regulation of ERBB2 (HER2) andGRB7. As noted in Figures 5 and 11 there is an apparent bimodal
distribution and ERBB2 and GRB7 do not uniformly over-express in this process. Given the split
observed in the dendrogram (Appendix 1) this may indicate two subprocesses, one with elevated
expression levels for these genes. However, we did not find a statistically significant difference
in clinical outcome for patients belonging to these two possible subclasses. The most aggressive
subtype is also the most well defined: it is clearly and consistently identified by both variants of
LPD (Figures 3 and 18(a)) and matches the basal subtype described by Sorlie et al (Figure 16).
This subtype is marked by abnormal expression of the transcription factor genes FOXA1, FOXC1,
GATA3, TFF3 and XBP1, for example, and it is associated with loss of regulation of the vascular
growth factor VEGF. As already remarked, using a sparse graphical model [7, 8], we find that the
transcription factor genes FOXA1, GATA3, TFF3 and XBP1 are closely linked with the estrogen
receptor-alpha gene, which with the estrogen pathway, plays a crucial role in the development of
many breast tumours. One target of ERα is the TFF1 gene and FOXA1 has a direct influence on
transcription by this gene since there are binding sites for FOXA1 in its promoter region [1]. A
number of other ERα-bound promoters have FOXA1 binding sites [16]. The role of FOXA1 has
been highlighted in a contemporary study by Laganiere et al [16]: expression by FOXA1 correlates
with the presense of ERα and it has been suggested that that this gene plays a crucial role in a
transcriptional domain governing estrogen response. Reinforcing this result, a contemporary study
by Carroll et al [4] has shown that forkhead factor binding sites are present in 54% of 57 ER
binding regions. This strongly supports the significance of abnormal expression of FOXA1 and
FOXC1 indicated by our analysis. Finally, in agreement with the analysis using a sparse graphical
model [7, 8], there appears to be an important role played by TFF3, a close relative of TFF1.
The decomposition proposed here is at most a basic model since one would expect further sub-
division as more data becomes available, thus enabling a higher resolution picture. As remarked
previously, the effects of noise are averaged out as the dataset size increases. Thus for the dataset
of Sorlie et al the peak in the likelihood curve is at 3-4 processes but, for the largest dataset of de
Vijver et al, it is approximately 4-5. Certainly, our analysis suggests that the 2 process split of de
Vijver et al [6] is too simple a model and at least 4 main processes are justified by the datasets
used. The dataset for West et al was exclusively based on invasive ductal tumours and the Sorlie
et al dataset had samples very predominantly of this type. However, use of samples consistently
of the same histological type would also help reduce noise and improve definition. The indolent
subtype 1 was not presented in the original analysis of Sorlie et al and the ability of the method
to find this feature highlights the importance of using Bayesian methods in this context.
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4 Appendix 1: Comparison with dendrogram of Sorlie et al
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Figure 16: A comparison between the dendrogram reported in Sorlie et al [25], Figure 1B, and
the decomposition by variational LPD given in Figure 2. To the left of the tree, the variational
LPD assignment to process is designated by the numbers 1 to 4. Beside these numbers are the
sample titles for identification with Sorlie et al [25], Figure 1B. Process assignment numbers are
missing in a few cases because the peak in Figure 2 (normalised γak, see equation 4, Appendix 2)
is ambiguous in its assignment of sample to process.
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5 Appendix 2: Latent Process Decomposition.
5.1 Variational Approach to LPD
We will briefly outline Latent Process Decomposition: for a more detailed description of the method
the reader is referred to Rogers et al. [23]. As remarked in the text, a sample can be represented
as a combinatorial mixture over multiple processes, in contrast to the implicit mutual exclusion
of classes assumption of most cluster analysis methods. Thus we have used process rather than
cluster to emphasis this difference with standard cluster analysis methods.
We are interested in constructing a model for the microarray data and this model will have param-
eters which we alter during the training process. We will suppose these parameters are r1, r2, . . . or,
as a set, R. Similarly the dataset will be denoted by D. Thus we wish to maximise the probability
of a model given the data, p(R|D), which from Bayes’s rule can also be written:
p(R|D) ∝ p(D|R)p(R) (1)
where p(D|R) is the likelihood and p(R) is the prior on our parameters R.
The approach we now outline is described in more detail elsewhere [23] and it adopts the Latent
Dirichlet Allocation (LDA) approach to data modelling [2], comparing favourably with alternatives
such as mixture models [18], Naive Bayes and other approaches (see [23]). In this approach we
incorporate prior beliefs in the form of reasonable distributional assumptions e.g. the (logged) gene
expression levels from a microarray experiment are assumed approximately normally distributed
(for Affymetrix data we use a prior affine translation to bring expression data into an approximate
N (0, 1) distribution). Unfortunately, we cannot estimate the above posterior probability directly
but we can lower bound this expression using Jensen’s inequality. Thus our approach parallels the
Latent Dirichlet Allocation method of Blei et al [2] which derives a similar lower bound for discrete
data. This lower bound is found using an efficient algorithmic technique, described below.
We are interested in finding the set of paramaters R that maximises p(R|D). In the case of a
uniform (or uninformative) prior, this is the maximum likelihood solution. We will begin by de-
riving the maximum likelihood solution and then extend the method to a non-uniform prior. The
log-likelihood of a set of A training samples is log p(D|µ,σ,α), where µ,σ,α are the model param-
eters, the process means, standard deviations and Dirichlet parameter respectively. Marginalising
over the latent variable θ allows us to expand this expression as follows
log p(D|µ,σ,α) =
A∑
a=1
log
∫
θ
p(a|µ,σ,θ)p(θ|α)dθ. (2)
A lower bound on this expression can be inferred by the introduction of two variational parameters
Qkga and γak and the following iterative update equations provide estimates for these parameters
Qkga =
N (ega|k, µgk, σgk) exp [ψ(γak)]∑K
k′=1N (ega|k, µgk′ , σgk′) exp [ψ(γak′)]
(3)
γak = αk +
G∑
g=1
Qkga (4)
for given αk, with process index k = 1, . . . ,K, and where N (. . .) is a normal distribution and ψ(z) is
the digamma function. For gene g and process k, µgk and σgk are the means and standard deviations
(for example, in Figure 5 these give the means and spreads for the 4 processes illustrated). γak,
normalised over the number of processes, gives the confidence of membership of sample a in process
k. Let ega denote the expression level for gene g in sample a, then the model parameters are
obtained from the following update equations:
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µgk =
∑A
a=1Qkgaega∑A
a′=1Qkga′
(5)
σ2gk =
∑A
a=1Qkga(ega − µgk)2∑A
a′=1Qkga′
(6)
The update rule for the Dirichlet model parameter αk is found from the derivatives of the α
dependent terms in the likelihood [2]. Thus the αk are modified after each iteration of the above
updatings using a standard Newton-Raphson technique (see [2] Appendix A.4.2 and [23]).
The above argument can be extended to a maximum posterior (MAP) solution with non-uniform
priors. Thus, a suitable prior on the means could be a Gaussian distribution with zero mean.
This would reflect a prior belief that for cDNA microarrays most genes will be uninformative and
will have logged expression ratios around zero (i.e. they are unchanged compared to a reference
sample). For the variance, we may wish to define a prior that penalises over-complex models and
avoids overfitting. Overfitting may occur when Gaussian functions contract onto a single data point
causing poor generalisation. With a suitable choice for the prior an extension of our model to a
full MAP solution is straightforward. Our combined likelihood and prior expression is (assuming
a uniform prior on α):
p(µ,σ,α|D) ∝ p(D|µ,σ,α)p(µ)p(σ). (7)
Taking the logarithm of both sides we see that the maximisation task is given by:
α,σ,µ = arg max
α,σ,µ
log p(G|µ,σ,α) + log p(µ) + log p(σ). (8)
Thus we can simply append these terms onto our bound on the log-likelihood. Noting that they
are functions of µ and σ only (and any associated hyper-parameters), we conclude that these extra
terms only change the update equations for µak and σak. Let us assume the following priors:
p(µgk) ∝ N (0, σµ) (9)
p(σ2gk) ∝ exp
{
− s
σ2ak
}
(10)
then we obtain the following new update equations instead:
µgk =
σ2µ
A∑
a=1
Qgkaega
σ2gk + σ2µ
A∑
a=1
Qgka
(11)
σ2gk =
A∑
a=1
Qgka(ega − µgk)2 + 2s
A∑
a=1
Qgka
. (12)
Once the model parameters have been estimated, we can calculate the likelihood for a collection
of A′ samples using:
L =
A′∏
a=1
∫
θ
{ G∏
g=1
K∑
k=1
N (ega|k, µgk, σgk)θk
}
p(θ|α)dθ (13)
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where we estimate the expectation over the Dirichlet distribution by averaging over N samples
drawn from the estimated Dirichlet prior p(θ|α)
L ≈
A′∏
a=1
1
N
N∑
n=1
{ G∏
g=1
K∑
k=1
N (ega|k, µgk, σgk)θkn
}
. (14)
Apart from using the likelihood to determine the best number of processes to use, it can be used to
determine the parameters used in the prior. In Figure 17 we plot likelihood curves as a function of
s, the prior parameter in equation (10). The peaks in these plots model the extent of noise in the
data and enables the algorithm to avoid constructing an over-complex model which would fit to
this noise. As reported elsewhere [23] the model is little affected by choice of the prior parameter
σµ in equation (9) and we have set this value to 0.1.
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Figure 17: Hold-out log-likelihood as a function of s for the datasets of Sorlie et al (left) and van
’t Veer et al (right).
5.2 A Markov Chain Monte Carlo approach to LPD
To validate the above variational method we re-derived the results using a Gibbs sampler-based
approach for the datasets of Sorlie et al and de Vijver et al. The starting point, equation (2), is the
same but otherwise the method is distinct. The approach we now describe is slow to execute (the
cross-validation study of the number of processes proved prohibitive). However, it supports the
results presented in the main text. Also, by using a Gibbs sampler we can obtain a full posterior
distribution for the model parameters and hence investigate the accuracy of the point estimate
approximations derived by the variational algorithm described above.
We implemented a standard Gibbs sampler [17] using conjugate priors for all model parameters.
Each variable in the algorithm was initialised randomly. We used a burn-in period to allow the
Monte Carlo algorithm to stabilise (100000 iterations for the Sorlie et al dataset and 40000 for de
Vijver et al). The next 10000 samplings were used to form the posterior distribution. To compare
with variational LPD we chose 4 processes. For process membership there is no γ parameter so
instead we determined membership from the normalised mode of the posterior distribution of θ.
For the Sorlie et al dataset we give the resulting Kaplan Meier plot in Figure 18(a), which can
be compared to Figure 3(a) from the variational approach. The posterior distribution over model
parameters supported the significance of genes already discussed. For example, in Figure 18(b)
we give the distribution over means for FOXA1 which can be compared to Figure 7(a) with point
estimates of the means from the variational approach.
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Figure 18: Kaplan Meier plot (left) and distribution of means (right) for FOXA1 from the MCMC
algorithm applied to the Sorlie et al dataset. For the Kaplan Meier plot there are 11 patients in
process 1, 30 in procss 2, 42 in process 3 and 18 in process 4. The right hand Figure shows the
distribution of means for a selected gene (FOXA1) indicating the reliability of the point estimates
of the means found using LPD (see Figure 7(a) for comparison).
For the dataset of de Vijver et al and using the MCMC approach, we give the Kaplan Meier plot
in Figure 19(a). As for the variational approach we find one indolent process and further processes
of increasing aggressiveness. For comparison with Figure 15(a) we give the distribution of means
for ORC6L in Figure 19(b).
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Figure 19: Kaplan Meier plot (left) using the MCMC approach for the de Vijver et al dataset. For
the Kaplan Meier plot there are 6 patients in process 1, 136 in procss 2, 103 in process 3 and 47
in process 4. The curves labelled 3 and 4 meet but do not cross. The right hand Figure shows the
distribution of means for ORC6L giving a similar progression to that observed in Figure 15(a).
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6 Appendix 3: Supplementary Material on the dataset of
De Vijver et al.
In the original publication of de Vijver et al [6] 21 cDNA sequences had no gene name or infor-
mation associated with them. Given this fact and the monotonic trends in mean expression values
mentioned in the main text we have updated and examined ontology information for the 70 genes
and their encoded proteins to examine their significance. A full description of all 70 entries and
further information is available as supplementary data at www.enm.bris.ac.uk/lpd/bc.htm. In the
table below we list the top ranked genes distinguishing process 1 vs process 4 (with Z1 > 2) for the
dataset of de Vijver et al. The 4 columns headed Process are the mean logged expression values
(using log base 10). The processes are ranked in order of most indolent (1) to most aggressive (4)
outcome. The end column highlights the progression trend across the 4 processes. Genes marked
BCSS1 and BCSS2 correspond to hypothetical genes: BCSS1 is ‘moderately similar to T50635
hypothetical protein’ and BCSS2 is ‘weakly similar to ISHUSS disulfide-isomerase’. The Z1 values
follow a normal probability distribution N (0, 1).
Of these genes, ORC6L is involved in DNA replication and serves as a platform for the assembly
of additional initiation factors such as CDC6 and MCM. siRNA gene silencing studies indicate
that ORC6L plays an essential role in coordinating chromosome replication and segregation with
cytokinesis. STK32B is a serine/threonine kinase. KIAA1442 encodes a transcription factor with
an IPT/TIG motif. These motifs are found in cell surface receptors such as Met and Ron as well
as in intracellular transcription factors where it is involved in DNA binding. Intriguingly the Ron
tyrosine kinase receptor shares with the members of its subfamily (Met and Sea) the control of cell
dissociation, motility, and invasion of extracellular matrices (scattering) [5]. Two genes have no
known function though Contig38288RC is weakly similar to ISHUSS protein disulfide-isomerase, an
enzyme that participates in the folding of proteins containing disulfide bonds. In the Table we have
labelled Contig55725RC as BCSS1 and Contig38288RC as BCSS2 (breast cancer survival signature
1 and 2). Many genes are involved in processes associated with tumour growth such as DNA
replication (MCM6), cell cycle control (CCNE2), spindle associated factors (NUSAP1, PRC1),
chromosome organisation (CENPA), actin filament assembly (DIAPH3) and vascular remodelling
(ITS). All these genes are up-regulated for the most aggressive process versus the least aggressive.
DIAPH3, which was unidentified in the original paper, appears three times in the 70 gene set.
21
Gene ID Gene name Process 1 Process 2 Process 3 Process 4 Z1 Trend
NM 014321 ORC6L −0.47 −0.32 −0.02 0.26 4.29 Up
Contig55725 RC BCSS1 −0.80 −0.54 −0.22 0.39 4.15 Up
NM 018401 STK32B 0.32 0.07 0.01 −0.11 3.14 Down
AB037863 KIAA1442 0.28 0.05 −0.01 −0.29 3.07 Down
Contig38288 RC BCSS2 −0.34 −0.16 −0.02 0.26 3.06 Up
NM 003981 PRC1 −0.45 −0.30 0.02 0.24 2.98 Up
NM 016359 NUSAP1 −0.50 −0.28 0.039 0.22 2.93 Up
NM 004702 CCNE2 −0.55 −0.32 −0.02 0.22 2.93 Up
NM 001809 CENPA −0.52 −0.41 −0.06 0.29 2.80 Up
AL137718 DIAPH3 −0.30 −0.10 0.03 0.22 2.78 Up
NM 014791 MELK −0.46 −0.21 0.01 0.26 2.71 Up
NM 016448 RAMP −0.36 −0.17 0.05 0.15 2.65 Up
Contig40831 RC AI224578 −0.39 −0.11 −0.05 0.19 2.57 Up
AL080059 TSPYL5 −0.53 −0.24 −0.15 0.25 2.50 Up
Contig46218 RC DIAPH3 −0.35 −0.22 0.04 0.27 2.50 Up
NM 003875 GMPS −0.34 −0.17 −0.05 0.21 2.45 Up
NM 020974 SCUBE2 0.24 0.19 −0.24 −0.99 2.39 Down
NM 000436 OXCT1 −0.29 −0.06 −0.10 0.15 2.37 Mixed
NM 005915 MCM6 −0.37 −0.14 0.00 0.23 2.31 Up
AA555029 RC AA555029 −0.31 −0.09 −0.06 0.15 2.27 Up
NM 002916 RFC4 −0.29 −0.133 −0.01 0.20 2.27 Up
AL080079 GPR126 −0.59 −0.25 −0.12 0.17 2.22 Up
NM 015984 UCHL5 −0.21 −0.08 −0.01 0.15 2.13 Up
Contig20217 RC TGS −0.33 −0.17 −0.02 0.17 2.08 Up
NM 006117 PECI 0.21 0.05 0.01 −0.25 2.07 Down
Contig32185 RC ITS −0.33 −0.14 −0.08 0.15 2.02 Up
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